BriaCell Therapeutics Corp. (BCTX)
NASDAQ: BCTX · Real-Time Price · USD
11.39
-0.85 (-6.94%)
At close: Dec 5, 2025, 4:00 PM EST
11.83
+0.44 (3.85%)
After-hours: Dec 5, 2025, 7:03 PM EST
BriaCell Therapeutics Employees
BriaCell Therapeutics had 16 employees as of July 31, 2023. The number of employees increased by 10 or 166.67% compared to the previous year.
Employees
16
Change
10
Growth
166.67%
Revenue / Employee
n/a
Profits / Employee
-$1,644,492
Market Cap
21.47M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jul 31, 2023 | 16 | 10 | 166.67% |
| Jul 31, 2021 | 6 | 0 | - |
| Aug 1, 2019 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BCTX News
- 4 days ago - BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025 - GlobeNewsWire
- 11 days ago - BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025 - GlobeNewsWire
- 16 days ago - BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics - GlobeNewsWire
- 18 days ago - BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025 - GlobeNewsWire
- 4 weeks ago - BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025 - GlobeNewsWire
- 4 weeks ago - BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models - GlobeNewsWire
- 6 weeks ago - BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer - GlobeNewsWire
- 6 weeks ago - BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study - GlobeNewsWire